

Set Name Query

side by side

Hit Count Set Name

result set

*DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ*L7 L6 same (cd40 or cd40L or cd40 adj ligand or cd20 or gp39)79 L7L6 ('24-31' or '89-76' or 'c2b8') same (antibod\$ or hybridoma\$)108 L6*DB=JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ*L5 (cd20) same (cd40L or cd40 adj ligand or gp39) and (leukemi\$)2 L5*DB=USPT,PGPB; PLUR=YES; OP=ADJ*L4 (cd20) same (cd40L or cd40 adj ligand or gp39) and (leukemi\$)33 L4L3 L1 and (cd20 or cd40 or cd40L or cd40 adj ligand or gp39)28 L3L2 L1 and (leukemi\$)33 L2L1 hanna-nabil\$44 L1

END OF SEARCH HISTORY

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 10 of 33 returned.**

-
- ☐ 1. [20030119029](#). 13 Aug 02. 26 Jun 03. Compositions and methods relating to novel benzodiazepine compounds and targets thereof. Glick, Gary D., et al. 435/6; 435/235.1 435/325 514/221 A61K031/5513 C12Q001/68 A61K031/55 A01N043/62 C12N007/00 C12N007/01 C12N005/00 C12N005/02.
-
- ☐ 2. [20030118592](#). 25 Jul 02. 26 Jun 03. Binding domain-immunoglobulin fusion proteins. Ledbetter, Jeffrey A., et al. 424/178.1; 530/391.1 A61K039/395 C07K016/46.
-
- ☐ 3. [20030103971](#). 12 Sep 02. 05 Jun 03. Immunoregulatory antibodies and uses thereof. Hariharan, Kandasamy, et al. 424/141.1; 424/155.1 A61K039/395.
-
- ☐ 4. [20030059763](#). 26 Jan 01. 27 Mar 03. Immunoglobulin class switch recombination. Saxon, Andrew, et al. 435/4; C12Q001/00.
-
- ☐ 5. [20030012781](#). 06 Jun 01. 16 Jan 03. Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof. Darrell, Anderson, et al. 424/131.1; 424/93.21 A61K048/00 A61K039/395.
-
- ☐ 6. [20030008342](#). 16 Nov 99. 09 Jan 03. SURFACE RECEPTOR ANTIGEN VACCINES. Scholler, Nathalie B., et al. 435/69.1; 435/320.1 536/23.1 C07H021/04 C12P021/02 C12N015/74.
-
- ☐ 7. [20020197256](#). 14 Mar 02. 26 Dec 02. Combination therapy. Grewal, Iqbal. 424/144.1; 424/155.1 A61K039/395.
-
- ☐ 8. [20020164346](#). 14 Feb 02. 07 Nov 02. Altered peptide ligands. Nicolette, Charles A.. 424/185.1; A61K039/00.
-
- ☐ 9. [20020147312](#). 30 Jan 02. 10 Oct 02. Hybrid antibodies and uses thereof. O'Keefe, Theresa, et al. 530/387.3; 530/388.15 C07K016/28.
-
- ☐ 10. [20020065241](#). 10 Aug 01. 30 May 02. Antigenic peptide concatomers. Shankara, Srinivas. 514/44; 424/450 424/93.21 536/23.5 A61K048/00 C07H021/04 A61K009/127.
-

[Generate Collection](#)[Print](#)

[Generate Collection](#)[Print](#)**Search Results - Record(s) 11 through 20 of 33 returned.**

-
- ☐ 11. [20020058029](#). 18 Sep 01. 16 May 02. Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination. Hanna, Nabil. 424/131.1; 424/144.1 A61K039/395.
-
- ☐ 12. [20020031522](#). 10 Mar 97. 14 Mar 02. TRUNCATED CRAFI INHIBITS CD40 SIGNALING. BALTIMORE, DAVID, et al. 424/185.1; 435/63 435/64 435/7.2 435/7.23 530/324 530/350 530/358 G01N033/53 G01N033/567 G01N033/574 C12P031/00 C12P029/00 A61K039/00 C07K005/00 C07K007/00 C07K016/00 C07K017/00 A61K038/00 C07K001/00 C07K014/00 A61K038/16.
-
- ☐ 13. [20020028178](#). 16 May 01. 07 Mar 02. Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications. Hanna, Nabil, et al. 424/1.49; 424/143.1 A61K039/395 A61K051/00.
-
- ☐ 14. [20020018766](#). 05 Apr 01. 14 Feb 02. Genes differentially expressed in cancer cells to design cancer vaccines. Roberts, Bruce L., et al. 424/93.21; 424/155.1 424/85.1 435/6 A61K048/00 C12Q001/68 A61K039/395 A61K038/19.
-
- ☐ 15. [20020009444](#). 25 Apr 01. 24 Jan 02. Intrathecal administration of rituximab for treatment of central nervous system lymphomas. Grillo-Lopez, Antonio J.. 424/142.1; 424/1.49 424/1.65 514/251 514/283 A61K051/10 A61K039/395 A61K051/04 A61K031/525 A61K031/475.
-
- ☐ 16. [20020006404](#). 31 Jan 01. 17 Jan 02. Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications. Hanna, Nabil, et al. 424/142.1; 424/155.1 A61K039/395.
-
- ☐ 17. [20010056066](#). 13 Jul 01. 27 Dec 01. Method of treating immune cell mediated systemic diseases. Bugelski, Peter John, et al. 514/8; 424/131.1 A61K038/16 A61K039/395.
-
- ☐ 18. [20010018041](#). 16 Apr 01. 30 Aug 01. Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy. Hanna, Nabil, et al. 424/1.49; 424/181.1 A61K039/395.
-
- ☐ 19. [6569997](#). 25 May 00; 27 May 03. Antibody specific for H4-1BB. Kwon; Byoung S.. 530/388.22; 424/130.1 424/184.1 435/252.3 435/6 435/69.1 435/69.5 435/7.2 435/7.21 436/501 530/350 536/23.5. C07K016/00.
-
- ☐ 20. [6506383](#). 14 Jun 99; 14 Jan 03. Methods of suppressing immune responses to transplanted tissues and organs with gp39-specific antibodies. Black; Amelia, et al. 424/154.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75. A61K039/395 C07K016/28.
-

[Generate Collection](#)[Print](#)

[Generate Collection](#)[Print](#)**Search Results - Record(s) 21 through 30 of 33 returned.**

-
- ☐ 21. [6465251](#). 13 Nov 96; 15 Oct 02. Method of promoting b-cell proliferation and activation with CD40 ligand and cyclosporin. Schultze; Joachim L., et al. 435/377; 435/2 435/325 435/326 435/352 435/355 435/363 435/366 435/372 435/372.1 435/372.2 435/374 435/375 435/376 435/383. C12N005/02 C12N005/06 C12N005/08 C12N005/12.
-
- ☐ 22. [6440418](#). 08 Sep 97; 27 Aug 02. Methods of treating autoimmune diseases with gp39-specific antibodies. Black; Amelia, et al. 424/154.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75. A61K039/395 C07K016/28.
-
- ☐ 23. [6303121](#). 14 Jan 98; 16 Oct 01. Method of using human receptor protein 4-1BB. Kwon; Byoung S.. 424/141.1; 424/138.1 424/139.1 424/144.1 530/350 530/351 530/388.22. A01N037/18 A61K038/00 A61K039/395.
-
- ☐ 24. [6150584](#). 02 Oct 96; 21 Nov 00. Human antibodies derived from immunized xenomice. Kucherlapati; Raju, et al. 800/18; 424/93.21 800/25 800/6. A61K048/00 C12N005/10 C12N015/07.
-
- ☐ 25. [6106832](#). 22 Jan 96; 22 Aug 00. Treatment of individuals exhibiting defective CD40L. Spriggs; Melanie K., et al. 424/134.1; 424/184.1 424/192.1 424/195.11 514/2 514/8 514/885. A61K038/19.
-
- ☐ 26. [6075181](#). 07 Jun 95; 13 Jun 00. Human antibodies derived from immunized xenomice. Kucherlapati; Raju, et al. 800/25; 800/18 800/21 800/4 800/6. A61K048/00 C12N015/09 C12N005/10.
-
- ☐ 27. [6001358](#). 07 Nov 95; 14 Dec 99. Humanized antibodies to human gp39, compositions containing thereof. Black; Amelia, et al. 424/154.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75 536/23.53. A61K039/395 C07K016/28.
-
- ☐ 28. [5877210](#). 05 Jun 95; 02 Mar 99. Phosphotyrosine phosphatase inhibitors or phosphotyrosine kinase activators for controlling cellular proliferation. Schieven; Gary L.. 514/492; 424/178.1 424/179.1 424/181.1 435/184 435/244 556/1 556/42 556/44. A01N055/02 A61K039/395 C07F053/00.
-
- ☐ 29. [5846998](#). 18 Jun 96; 08 Dec 98. Use of phosphotyrosine phosphatase inhibitors or phosphotyrosine kinase activators for controlling cellular proliferation. Schieven; Gary L.. 514/492; 424/617 424/646 435/184 435/326 556/1 556/42 556/44. A01N055/02 A01N059/16 C12N009/99 C07F053/00.
-
- ☐ 30. [5693627](#). 25 May 95; 02 Dec 97. Use of phosphotyrosine phosphatase inhibitors for controlling cellular proliferation. Schieven; Gary L.. 514/137; 435/184 435/244 514/141 564/12 568/14 568/17. A61K031/66 C12N009/99 C12N001/38 C07F009/02.
-

[Generate Collection](#)[Print](#)

Generate Collection

Print

Search Results - Record(s) 31 through 33 of 33 returned.

- ☐ 31. 5583242. 25 May 95; 10 Dec 96. Use of phosphotyrosine phosphatase inhibitors for controlling cellular proliferation. Schieven; Gary L.. 556/44; 556/1 556/114 556/116 556/117 556/42. C07F005/00.
- ☐ 32. 5565491. 31 Jan 94; 15 Oct 96. Use of phosphotyrosine phosphatase inhibitors for controlling cellular proliferation. Schieven; Gary L.. 514/492; 514/499 556/1 556/114 556/116 556/117 556/42 556/44. A61K031/28 A61K031/30 C07F001/08 C07F005/00.
- ☐ 33. 5565321. 21 Jan 94; 15 Oct 96. Detection of mutations in a CD40 ligand gene. Spriggs; Melanie K., et al. 435/6; 435/7.1 435/91.1 536/23.1 536/23.5 536/24.3 536/24.31. C12F019/34 C12Q001/68 G01N033/50.

Generate Collection

Print

Term	Documents
CD20	1271
CD20S	0
CD40L	851
CD40LS	2
CD40	2202
CD40S	0
LIGAND	57464
LIGANDS	47106
GP39	232
GP39S	0
LEUKEMIS	0
((CD20) SAME (CD40L OR CD40 ADJ LIGAND OR GP39) AND (LEUKEMIS)).USPT,PGPB.	33

There are more results than shown above. Click here to view the entire set.

[Previous Page](#)[Next Page](#)

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Term	Documents
CD40	2482
CD40S	0
CD40L	928
CD40LS	2
LIGAND	82251
LIGANDS	57709
CD20	1368
CD20S	0
GP39	275
GP39S	0
(6 SAME ((GP39 OR CD40L OR CD20 OR CD40) OR (CD40 ADJ LIGAND))).USPT,PGPB,JPAB,EPAB,DWPI.	79
(L6 SAME (CD40 OR CD40L OR CD40 ADJ LIGAND OR CD20 OR GP39)).USPT,PGPB,JPAB,EPAB,DWPI.	79

Database: US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

L7

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History****DATE:** Friday, June 27, 2003 [Printable Copy](#) [Create Case](#)

Term	Documents
CD20	1271
CD20S	0
CD40L	851
CD40LS	2
CD40	2202
CD40S	0
LIGAND	57464
LIGANDS	47106
GP39	232
GP39S	0
LEUKEMIS	0
((CD20) SAME (CD40L OR CD40 ADJ LIGAND OR GP39) AND (LEUKEMIS)).USPT,PGPB.	33

There are more results than shown above. Click here to view the entire set.

[Previous Page](#)

[Next Page](#)

Term	Documents
CD20	1271
CD20S	0
CD40L	851
CD40LS	2
CD40	2202
CD40S	0
LIGAND	57464
LIGANDS	47106
GP39	232
GP39S	0
LEUKEMIS	0
((CD20) SAME (CD40L OR CD40 ADJ LIGAND OR GP39) AND (LEUKEMIS)).USPT,PGPB.	33

There are more results than shown above. Click here to view the entire set.

[Previous Page](#)

[Next Page](#)

Term	Documents
CD20	1271
CD20S	0
CD40L	851
CD40LS	2
CD40	2202
CD40S	0
LIGAND	57464
LIGANDS	47106
GP39	232
GP39S	0
LEUKEMIS	0
((CD20) SAME (CD40L OR CD40 ADJ LIGAND OR GP39) AND (LEUKEMIS)).USPT,PGPB.	33

There are more results than shown above. Click here to view the entire set.

[Previous Page](#)

[Next Page](#)

s (24(w)31 or 89(w)76 or c2b8) (20n) (antibod? or hybridoma?) and (Cd20 or cd40L or cd40(w)ligand or gp39)

```

1301928 24
503721 31
1050 24(W)31
201923 89
229499 76
94 89(W)76
263 C2B8
1807045 ANTIBOD?
47845 HYBRIDOMA?
210 ((24(W)31 OR 89(W)76) OR C2B8) (20N) (ANTIBOD? OR
HYBRIDOMA?)
10006 CD20
4500 CD40L
18006 CD40
348210 LIGAND
8235 CD40(W)LIGAND
574 GP39

```

S8 179 (24(W)31 OR 89(W)76 OR C2B8) (20N) (ANTIBOD? OR HYBRIDOMA?)
AND (CD20 OR CD40L OR CD40(W)LIGAND OR GP39)

? rd s8

...examined 50 records (50)

...examined 50 records (100)

...examined 50 records (150)

...completed examining records

S9 98 RD S8 (unique items)

? ds

Set	Items	Description
S1	31	AU='HANNA NABIL'
S2	31	RD S1 (unique items)
S3	3	S2 AND LEUKEMI?
S4	3	RD S3 (unique items)
S5	0	(CD20) (10N) (ANTIBOD?) AND (CD40L OR CD40(W)LIGAND OR GP39) - (10N) (ANTIBOD?) AND LEUKEMI?
S6	21	(CD20) AND (CD40L OR CD40(W)LIGAND OR GP39) AND LEUKEMI?
S7	19	RD S6 (unique items)
S8	179	(24(W)31 OR 89(W)76 OR C2B8) (20N) (ANTIBOD? OR HYBRIDOMA?) - AND (CD20 OR CD40L OR CD40(W)LIGAND OR GP39)
S9	98	RD S8 (unique items)
?		

begin 5,73,155,399
 27jun03 16:21:44 User208760 Session D2318.2
 \$0.00 0.070 DialUnits File410
 \$0.00 Estimated cost File410
 \$0.01 TELNET
 \$0.01 Estimated cost this search
 \$0.32 Estimated total session cost 0.157 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 5:Biosis Previews(R) 1969-2003/Jun.W4
 (c) 2003 BIOSIS

File 73:EMBASE 1974-2003/Jun W4
 (c) 2003 Elsevier Science B.V.

*File 73: Alert feature enhanced for multiple files, duplicates removal, customized scheduling. See HELP ALERT.

File 155:MEDLINE(R) 1966-2003/Jun W4
 (c) format only 2003 The Dialog Corp.

*File 155: Medline has been reloaded and accession numbers have changed. Please see HELP NEWS 155.

File 399:CA SEARCH(R) 1967-2003/UD=13826
 (c) 2003 American Chemical Society

*File 399: Use is subject to the terms of your user/customer agreement. Alert feature enhanced for multiple files, etc. See HELP ALERT.

Set Items Description

? e ah=hanna nabil ?

Ref	Items	Index-term
E1	1	AD=990625
E2	1	AD=991127
E3	0	*AH=HANNA NABIL ?
E4	1	AN=AE 40
E5	1	AN=AM 105531
E6	1	AN=AM 20000032
E7	1	AN=AM 20000063
E8	1	AN=AM 20000084
E9	1	AN=AM 20010003
E10	1	AN=AM 2001077
E11	1	AN=AM 411
E12	1	AN=AM 412

Enter P or PAGE for more

? e au=hanna nabil ?

Ref	Items	Index-term
E1	6	AU=HANNA N.S.
E2	31	AU=HANNA NABIL
E3	0	*AU=HANNA NABIL ?
E4	1	AU=HANNA NADAR
E5	3	AU=HANNA NADER
E6	13	AU=HANNA NADER N
E7	4	AU=HANNA NAEEM
E8	5	AU=HANNA NAEEM B
E9	3	AU=HANNA NANCY
E10	1	AU=HANNA NASHAT F
E11	6	AU=HANNA NASSER
E12	4	AU=HANNA NASSER H

Enter P or PAGE for more

? s e2

S1 31 AU='HANNA NABIL'

? rd s1

...completed examining records

S2 31 RD S1 (unique items)
? s s2 and leukemia?
31 S2
523094 LEUKEMI?
S3 3 S2 AND LEUKEMI?
? rd s3
...completed examining records
S4 3 RD S3 (unique items)
? t s4/3/all

4/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

13790357 BIOSIS NO.: 200200419178
Induction of apoptosis by IDEC-152 (anti-CD23) in chronic lymphocytic
leukemia.
AUTHOR: Pathan Nuzhat(a); Hariharan Kandasamy; Berquist Lisa; Hopkins
Michael; Saven Alan; Reff Mitchell; Grint Paul; **Hanna Nabil**
AUTHOR ADDRESS: (a)IDEC Pharmaceuticals, San Diego, CA**USA
JOURNAL: Proceedings of the American Association for Cancer Research Annual
Meeting 43p1005 March, 2002
MEDIUM: print
CONFERENCE/MEETING: 93rd Annual Meeting of the American Association for
Cancer Research San Francisco, California, USA April 06-10, 2002
ISSN: 0197-016X
RECORD TYPE: Citation
LANGUAGE: English

4/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

13557864 BIOSIS NO.: 200200186685
Induction of apoptosis by IDEC-152 (anti-CD23) in lymphoma cells.
AUTHOR: Pathan Nuzhat(a); Hariharan Kandasamy(a); Hopkins Michael; Saven
Alan; Reff Mitchell(a); **Hanna Nabil**(a); Grint Paul(a)
AUTHOR ADDRESS: (a)IDEC Pharmaceuticals, San Diego, CA**USA
JOURNAL: Blood 98 (11 Part 1):p367a November 16, 2001
MEDIUM: print
CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of
Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001
ISSN: 0006-4971
RECORD TYPE: Abstract
LANGUAGE: English

4/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

11217379 BIOSIS NO.: 199799838524
Antigen formulation for recombinant cancer vaccines.
AUTHOR: **Hanna Nabil**; Black Amelia; Hariharan Kandasamy
AUTHOR ADDRESS: IDEC Pharm. Corp., 11011 Torreyana Rd., San Diego, CA
92121**USA
JOURNAL: International Journal of Oncology 11 (SUPPL.):p924 1997
CONFERENCE/MEETING: 2nd World Congress on Advances in Oncology Athens,
Greece October 16-18, 1997
ISSN: 1019-6439
RECORD TYPE: Citation
LANGUAGE: English
? s (cd20)(10n)(antibod\$) and (cd40L or cd40(w)ligand or gp39)(10n)antibod?) and
leukemi?

>>>Unmatched parentheses

? s (cd20) (10n) (antibod\$) and (cd40L or cd40(w)ligand or gp39) (10n) (antibod?) and leukemia?

10006 CD20
0 ANTIBOD\$
0 CD20(10N)ANTIBOD\$
4500 CD40L
18006 CD40
348210 LIGAND
8235 CD40(W)LIGAND
574 GP39
1807045 ANTIBOD?
1788 ((CD40L OR CD40(W)LIGAND) OR GP39) (10N)ANTIBOD?
523094 LEUKEMI?

S5 0 (CD20) (10N) (ANTIBOD\$) AND (CD40L OR CD40(W)LIGAND OR GP39) (10N) (ANTIBOD?) AND LEUKEMI?

? s (cd20) and (cd40L or cd40(w)ligand or gp39) and leukemia?

10006 CD20
4500 CD40L
18006 CD40
348210 LIGAND
8235 CD40(W)LIGAND
574 GP39
523094 LEUKEMI?

S6 21 (CD20) AND (CD40L OR CD40(W)LIGAND OR GP39) AND LEUKEMI?

? rd s6

...completed examining records

S7 19 RD S6 (unique items)

? t s7/3/all

7/3/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2003 BIOSIS. All rts. reserv.

13107668 BIOSIS NO.: 200100314817

Enhancement of antibody dependent cellular cytotoxicity (ADCC) against malignant B cells by trimeric **CD40L**.

AUTHOR: Jia Li(a); Epstein Alan(a); Douer Dan(a); Mohrbacher Ann(a)

AUTHOR ADDRESS: (a)University of Southern California, Los Angeles, CA**USA

JOURNAL: Blood 96 (11 Part 2):p288b-289b November 16, 2000

MEDIUM: print

CONFERENCE/MEETING: 42nd Annual Meeting of the American Society of

Hematology San Francisco, California, USA December 01-05, 2000

SPONSOR: American Society of Hematology

ISSN: 0006-4971

RECORD TYPE: Abstract

LANGUAGE: English

SUMMARY LANGUAGE: English

7/3/2 (Item 2 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2003 BIOSIS. All rts. reserv.

11447606 BIOSIS NO.: 199800228938

Chronic lymphocytic leukemia B cells can express **CD40**

ligand and demonstrate T-cell type costimulatory capacity.

AUTHOR: Schattner Elaine J(a); Mascarenhas John; Reyfman Inna; Koshy Mary;

Woo Caroline; Friedman Steven M; Crow Mary K

AUTHOR ADDRESS: (a)Room C-640, Cornell Univ. Med. Coll., 1300 York Ave.,

New York, NY 10021**USA

JOURNAL: Blood 91 (8):p2689-2697 April 15, 1998

ISSN: 0006-4971

DOCUMENT TYPE: Article

RECORD TYPE: Abstract
LANGUAGE: English

7/3/3 (Item 3 from file: 5)
DIALOG(R)File 5: Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

09615532 BIOSIS NO.: 199598070450
In vitro culturing of **leukemic** B cells from CLL patients using feeder cells and **CD40 ligand**.
AUTHOR: Buske C(a); Gogowski G; Feuring-Buske M; Koenemann S; Widmer M; Banchereau J; Lebien T W; Schreiber K; Hiddemann W; Woermann B
AUTHOR ADDRESS: (a)Dep. Intern. Med., Univ. Goettingen, Goettingen**Germany
JOURNAL: Blood 84 (10 SUPPL. 1):p454A 1994
CONFERENCE/MEETING: Abstracts Submitted to the 36th Annual Meeting of the American Society of Hematology Nashville, Tennessee, USA December 2-6, 1994
ISSN: 0006-4971
RECORD TYPE: Citation
LANGUAGE: English

7/3/4 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

12085976 EMBASE No: 2003197250
New directions in the diagnosis and treatment of chronic lymphocytic leukaemia
Schriever F.; Huhn D.
Dr. F. Schriever, Gartenstr. 26, 85456 Wartenberg Germany
AUTHOR EMAIL: folke.schriever@t-online.de
Drugs (DRUGS) (New Zealand) 2003, 63/10 (953-969)
CODEN: DRUGA ISSN: 0012-6667
DOCUMENT TYPE: Journal ; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 108

7/3/5 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

11654934 EMBASE No: 2002227184
Immunotherapy of chronic lymphocytic **leukemia**
Wierda W.G.; O'Brien S.
S. O'Brien, UT MD Anderson Cancer Center, Department of Leukemia, 1515 Holcombe Boulevard, Houston, TX 77030 United States
Expert Review of Anticancer Therapy (EXPERT REV. ANTICANCER THER.) (United Kingdom) 2001, 1/1 (73-83)
CODEN: ERATB ISSN: 1473-7140
DOCUMENT TYPE: Journal ; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 94

7/3/6 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

11567455 EMBASE No: 2002139082
Immunomodulatory gene therapy for haematological malignancies
Schmidt-Wolf G.D.; Schmidt-Wolf I.G.H.

I.G.H. Schmidt-Wolf, Medizinische Univ. Klin./Poliklin. I,
Sigmund-Freud-Str. 25, 53105 Bonn Germany
AUTHOR EMAIL: picasso@uni-bonn.de
British Journal of Haematology (BR. J. HAEMATOL.) (United Kingdom)
2002, 117/1 (23-32)
CODEN: BJHEA ISSN: 0007-1048
DOCUMENT TYPE: Journal ; Review
LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 82

7/3/7 (Item 4 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

11493192 EMBASE No: 2002064859
Surface antigen expression in chronic lymphocytic leukemia:
Clustering analysis, interrelationships and effects of chromosomal
abnormalities
Hulkkonen J.; Vilpo L.; Hurme M.; Vilpo J.
J. Vilpo, Department of Clinical Chemistry, Tampere University Hospital,
PO Box 2000, FIN-33521 Tampere Finland
Leukemia (LEUKEMIA) (United Kingdom) 2002, 16/2 (178-185)
CODEN: LEUKE ISSN: 0887-6924
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 40

7/3/8 (Item 5 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

07642174 EMBASE No: 1999127877
Expression of CD40/CD40 ligand and Bcl-2 family proteins in
labial salivary glands of patients with Sjogren's syndrome
Nakamura H.; Kawakami A.; Tominaga M.; Migita K.; Kawabe Y.; Nakamura T.;
Eguchi K.
Prof. K. Eguchi, First Dept. of Internal Medicine, Nagasaki University
Sch. of Medicine, 1-7-1 Sakamoto, Nagasaki City, Nagasaki 852-8501 Japan
Laboratory Investigation (LAB. INVEST.) (United States) 1999, 79/3
(261-269)
CODEN: LAINA ISSN: 0023-6837
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 29

7/3/9 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2003 The Dialog Corp. All rts. reserv.

09921324 21831292 PMID: 11842396
Advances in classification and therapy of indolent B-cell malignancies.
Kipps Thomas J
Department of Medicine, University of California, San Diego School of
Medicine, La Jolla, CA 92093, USA.
Seminars in oncology (United States) Feb 2002, 29 (1 Suppl 2)
p98-104, ISSN 0093-7754 Journal Code: 0420432
Document type: Journal Article; Review; Review, Tutorial
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

7/3/10 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

138235807 CA: 138(16)235807a JOURNAL
Surface antigen expression and correlation with variable heavy-chain gene
mutation status in chronic lymphocytic leukemia
AUTHOR(S): Vilpo, Juhani; Tobin, Gerard; Hulkkonen, Janne; Hurme, Mikko;
Thunberg, Ulf; Sundstrom, Christer; Vilpo, Leena; Rosenquist, Richard
LOCATION: Department of Clinical Chemistry, University of Tampere Medical
School, Laboratory Center of Tampere University Hospital, Tampere, Finland
JOURNAL: Eur. J. Haematol. (European Journal of Haematology) DATE: 2003
VOLUME: 70 NUMBER: 1 PAGES: 53-59 CODEN: EJHAEC ISSN: 0902-4441
LANGUAGE: English PUBLISHER: Blackwell Munksgaard

7/3/11 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

137336712 CA: 137(23)336712a PATENT
Maturation of antigen-presenting cells using activated t cells
INVENTOR(AUTHOR): Berenson, Ronald Jay; Bonyhadi, Mark; Craig, Stewart;
Kalamasz, Dale; Monji, Tatsue
LOCATION: USA
ASSIGNEE: Xcyte Therapies, Inc.
PATENT: PCT International ; WO 200287627 A1 DATE: 20021107
APPLICATION: WO 2002US13616 (20020429) *US PV287168 (20010427) *US
PV295331 (20010601)
PAGES: 70 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-048/00A;
C12N-005/02B; C12N-005/12B; C12N-015/63B DESIGNATED COUNTRIES: AE; AG; AL;
AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK;
DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE;
KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ;
NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TN; TR; TT;
TZ; UA; UG; US; UZ; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM
DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW;
AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR;
BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

7/3/12 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

137153822 CA: 137(11)153822s PATENT
CD23 antagonistic antibodies for treatment of neoplastic disorders
INVENTOR(AUTHOR): Hariharan, Kandasamy; Hanna, Nabil; Braslawsky, Gary R.
; Pathan, Nuzhat
LOCATION: USA
ASSIGNEE: Idec Pharmaceuticals Corporation
PATENT: PCT International ; WO 200260484 A1 DATE: 20020808
APPLICATION: WO 2002US2620 (20020131) *US 772938 (20010131) *US 855717
(20010516) *US 985646 (20011105)
PAGES: 88 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-045/00A;
A61K-045/06B; A61K-039/395B; A61P-035/00B; A61P-035/02B; A61K-039/395B;
A61K-031/70B DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG;
BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB;
GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR;
LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO;
RU; SD; SE; SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VN; YU;
ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM
; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; CH; CY; DE; DK; ES;

FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

7/3/13 (Item 4 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

137139366 CA: 137(10)139366q PATENT
Immunoregulatory antibodies and uses thereof
INVENTOR(AUTHOR): Hariharan, Kandasamy; Hanna, Nabil
LOCATION: USA
ASSIGNEE: Idec Pharmaceuticals Corporation
PATENT: PCT International ; WO 200260485 A2 DATE: 20020808
APPLICATION: WO 2002US2621 (20020131) *US 772938 (20010131) *US 855717 (20010516) *US 985646 (20011105) *US PV331187 (20011109)
PAGES: 103 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-045/00A; A61K-045/06B; A61K-039/395B; A61P-035/00B; A61P-035/02B
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

7/3/14 (Item 5 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

136117380 CA: 136(8)117380s PATENT
Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
INVENTOR(AUTHOR): Hanna, Nabil; Hariharan, Kandasamy
LOCATION: USA
ASSIGNEE: Idec Pharmaceuticals Corporation
PATENT: PCT International ; WO 200204021 A1 DATE: 20020117
APPLICATION: WO 2001US15677 (20010516) *US PV217706 (20000712) *US 772938 (20010131)
PAGES: 88 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/395; C07K-016/32 DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

7/3/15 (Item 6 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

136101104 CA: 136(7)101104u PATENT
Immunotherapy of B cell malignancies using a combination of cell depleting antibodies and antibodies to costimulatory molecules
INVENTOR(AUTHOR): Hanna, Nabil; Hariharan, Kandasamy
LOCATION: USA
ASSIGNEE: Idec Pharmaceuticals Corporation

PATENT: U.S. Pat. Appl. Publ. ; US 20020006404 A1 DATE: 20020117
APPLICATION: US 772938 (20010131) *US 435992 (19991108)
PAGES: 27 pp., Cont.-in-part of U.S. Ser. No. 435,992. CODEN: USXXCO
LANGUAGE: English CLASS: 424142100; A61K-039/395

7/3/16 (Item 7 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

136068707 CA: 136(5)68707t PATENT
Treatment of B-cell associated diseases such as malignancies and
autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22
antibody combination
INVENTOR(AUTHOR): White, Christine
LOCATION: USA
ASSIGNEE: Idec Pharmaceuticals Corporation
PATENT: PCT International ; WO 200197858 A2 DATE: 20011227
APPLICATION: WO 2001US18939 (20010614) *US PV212668 (20000620)
PAGES: 59 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-051/00A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI;
SK; SL; TJ; TM; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ;
MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ
; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL;
PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

7/3/17 (Item 8 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

134365708 CA: 134(26)365708x PATENT
Treatment of B cell malignancies using anti-CD40L antibodies in
combination with anti-CD20 antibodies and/or chemotherapeutics and
radiotherapy
INVENTOR(AUTHOR): Hanna, Nabil; Hariharan, Kandasamy
LOCATION: USA
ASSIGNEE: Idec Pharmaceuticals Corporation
PATENT: PCT International ; WO 200134194 A1 DATE: 20010517
APPLICATION: WO 2000US30426 (20001106) *US 435992 (19991108)
PAGES: 52 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/395A;
A61K-051/10B; A61P-035/02B DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU;
AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES;
FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC;
LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO;
RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZW;
AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW
; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR;
IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR;
NE; SN; TD; TG

7/3/18 (Item 9 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

133149142 CA: 133(11)149142v PATENT
Production of tetravalent antibodies
INVENTOR(AUTHOR): Braslawsky, Gary Ronald; Hanna, Nabil; Hariharan,
Kandasamy; Labarre, Michael J.; Huynh, Tri B.
LOCATION: USA

ASSIGNEE: Idec Pharmaceuticals Corporation
PATENT: PCT International ; WO 200044788 A1 DATE: 20000803
APPLICATION: WO 2000US1893 (20000128) *US 238741 (19990128)
PAGES: 65 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07K-016/00A;
C07K-016/28B; C07K-016/46B; A61K-039/395B; A61P-035/00B; A61P-035/02B;
A61P-037/00B DESIGNATED COUNTRIES: AE; AL; AM; AT; AU; AZ; BA; BB; BG; BR;
BY; CA; CH; CN; CR; CU; CZ; DE; DK; DM; EE; ES; FI; GB; GD; GE; GH; GM; HR;
HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA;
MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ;
TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU;
TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SL; SZ; TZ; UG; ZW; AT
; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF;
BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

7/3/19 (Item 10 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

133003706 CA: 133(1)3706k PATENT
Membrane antigenic structure inducing stoppage of proliferation and
apoptosis of activated T-lymphocytes
INVENTOR(AUTHOR): Huez, Georges; Majjaj, Samira; Kruys, Veronique;
Droogmans, Louis; Deblandre, Gisele
LOCATION: Belg.
ASSIGNEE: Universite Libre de Bruxelles
PATENT: PCT International ; WO 200031138 A1 DATE: 20000602
APPLICATION: WO 99BE149 (19991119) *BE 98835 (19981119)
PAGES: 49 pp. CODEN: PIXXD2 LANGUAGE: French CLASS: C07K-014/705A;
C07K-016/28B DESIGNATED COUNTRIES: AE; AL; AM; AT; AU; AZ; BA; BB; BG; BR;
BY; CA; CH; CN; CR; CU; CZ; DE; DK; DM; EE; ES; FI; GB; GD; GE; GH; GM; HR;
HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD;
MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM;
TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ;
TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SL; SZ; TZ; UG; ZW; AT; BE
; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ;
CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG
? s (24(w)31 or 89(w)76 or c2b8) (20n) (antibod? or hybridoma?) and (Cd20 or cd40L or
cd40(w)ligand or gp39)
1301928 24
503721 31
1050 24(W)31
201923 89
229499 76
94 89(W)76
263 C2B8
1807045 ANTIBOD?
47845 HYBRIDOMA?
210 ((24(W)31 OR 89(W)76) OR C2B8) (20N) (ANTIBOD? OR
HYBRIDOMA?)
10006 CD20
4500 CD40L
18006 CD40
348210 LIGAND
8235 CD40(W)LIGAND
574 GP39
S8 179 (24(W)31 OR 89(W)76 OR C2B8) (20N) (ANTIBOD? OR HYBRIDOMA?)
AND (CD20 OR CD40L OR CD40(W)LIGAND OR GP39)
?